Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apabetalone - Resverlogix

Drug Profile

Apabetalone - Resverlogix

Alternative Names: RVX-000222; RVX-208

Latest Information Update: 28 Jul 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Resverlogix Corporation
  • Class Anti-inflammatories; Antidementias; Antihyperlipidaemics; Antihypertensives; Antiretrovirals; Cardiovascular therapies; Nootropics; Quinazolines; Small molecules; Urologics
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Phase III Acute coronary syndromes; Atherosclerosis; Low HDL cholesterol
  • Phase II Prediabetic state
  • Preclinical Fabry's disease; HIV infections; Pulmonary arterial hypertension; Renal failure
  • No development reported Alzheimer's disease

Most Recent Events

  • 28 Jul 2019 No recent reports of development identified for phase-I development in Acute coronary syndromes in New Zealand (PO, Capsule)
  • 18 Mar 2019 Preclinical trials in Fabry's disease in Canada (PO)
  • 18 Mar 2019 Resverlogix and Laval University plan an early phase I pilot study (BRD4i) in Pulmonary arterial hypertension (In adults, In the elderly, Second-line therapy or greater) in Canada in the first half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top